- Home
- CHNR vs BGMS Comparison
CHNR vs BGMS Comparison
Compare CHNR & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHNR | BGMS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.0M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | BGMS |
|---|---|---|
| Price | $3.37 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.9K | ★ 30.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.74 |
| 52 Week High | $57.47 | $6.70 |
Technical Indicators
Market Signals| Indicator | CHNR | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 37.14 |
| Support Level | $3.35 | $0.74 |
| Resistance Level | $4.06 | $1.12 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 18.00 | 7.63 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.